Conductive, self-doping and biodegradable oligoEDOT-heparin biomaterial for improved electromechanical coupling, cardiac cell retention and delivery of paracrine factors

Descrizione del progetto

Un innovativo biomateriale per una migliore terapia cellulare in seguito a infarto cardiaco

La terapia cellulare post-infarto cardiaco ha mostrato risultati promettenti in termini di riduzione delle dimensioni di questa necrosi. Essa, tuttavia, non può invertire il danno al miocardio e la fibrosi. L’obiettivo del progetto HepEDOT, finanziato dall’UE, è quello di promuovere la rimuscolarizzazione cardiaca migliorando la ritenzione delle cellule dopo la terapia e superando i potenziali effetti collaterali come l’aritmia indotta dall’innesto. A questo scopo, i ricercatori testeranno un substrato biodegradabile costituito di un biomateriale a base di eparina capace di sostenere le cellule cardiache e di ottimizzare la conduttività elettrica. I risultati potrebbero migliorare la terapia cellulare cardiaca quale intervento terapeutico a seguito di infarto cardiaco.

Obiettivo

Cell therapy has emerged as a promising therapeutic strategy for cardiac repair, showing modest cardiomyocyte protection and infarct size reduction. It is under debate whether these outcomes are due to the implanted cells or their paracrine factors, as cells are scarce within a few weeks post-implantation. Regardless, this is still not sufficient to promote cardiac remuscularization and reverse medium to severe myocardium injury and fibrosis. Improved cell retention has been achieved with a substantial bulk of implanted cells, but highly associated to graft-induced arrhythmia, representing a significant challenge for clinical translation. The present study seeks to promote cardiac remuscularization after infarct, by improving the retention of cardiac cells and their paracrine factors without causing graft-induced arrhythmia. To do so, a conductive, self-doping and biodegradable oligoEDOT-heparin biomaterial will be synthesized and studied on in vitro and in vivo cardiac infarct models. The conductive EDOT oligomer moiety is envisaged to act as an electrical sink to shield the cardiac tissue from mismatched electromechanical impulses, while heparin will facilitate cardiac cell support and loading of regenerative factors, besides its recently documented doping capacity. The results of this fellowship are expected to overcome low cell retention and graft-induced arrhythmia, two of the biggest obstacles for translation in cardiac cell therapy, but also contribute with new insights regarding conductivity in materials and biological systems, to multiple fields of materials chemistry, medicine and bioelectronics. The world-class academic environment, collaborations and combined interdisciplinary expertise in biomaterials and cardiovascular sciences make the proposed fellowship activities ideally placed for enhancing my career prospects and consolidating my host and Europe in a leading position for translational research.

Campo scientifico

Programma(i)

Argomento(i)

MSCA-IF-2018 - Individual Fellowships

Invito a presentare proposte

H2020-MSCA-IF-2018

Vedi altri progetti per questo bando

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Coordinatore

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Contribution nette de l'UE

€ 224 933,76

Indirizzo

South kensington campus exhibition road
SW7 2AZ London
Regno Unito

Regione

London Inner London — West Westminster

Tipo di attività

Higher or Secondary Education Establishments

Collegamenti

Contatta l’organizzazione Sito web

Partecipazione a programmi di R&I dell'UE

Rete di collaborazione HORIZON

Altri finanziamenti

€ 0,00